Filing Details
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) filed a Form 8-K with the Securities and Exchange Commission on July 24, 2026, disclosing a material event.
8k filedNASDAQ:JAZZ
Jazz Pharmaceuticals plc (JAZZ) Reports Material Event to SEC
Filing Details Jazz Pharmaceuticals plc (NASDAQ:JAZZ) filed a Form 8-K with the Securities and Exchange Commission on July 24, 2026, disclosing a material event. Market Context…
Market Context
Jazz Pharmaceuticals plc's stock currently trades at $253.87 with a market capitalization of $10.0B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Jazz Pharmaceuticals plc's stock.
All SEC filings for Jazz Pharmaceuticals plc are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View JAZZ Stock Page
Frequently Asked Questions
Where can I read JAZZ's SEC filings?
Browse all filings on our JAZZ SEC filings page.
What types of SEC filings does Jazz Pharmaceuticals plc file?
Public companies like Jazz Pharmaceuticals plc file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
